NasdaqGS:REGNBiotechs
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN)
In July 2026, Telix Pharmaceuticals announced it had entered a collaboration with Regeneron Pharmaceuticals to co-develop and commercialize next-generation radiopharmaceutical cancer therapies, with Telix receiving an initial non-refundable US$40 million payment on signing.
Soon after, Regeneron was hit with a securities class action lawsuit alleging misleading disclosures about a Phase III Fianlimab-Libtayo trial, highlighting legal and credibility questions around its oncology pipeline...